NASDAQ:VERUVeru Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Veru Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.72 -0.31 (-10.23 %) (As of 08/13/2020 04:00 PM ET) Add Compare Share Today's Range$2.70Now: $2.72▼$2.9950-Day Range$2.83MA: $3.15▼$3.4652-Week Range$1.67Now: $2.72▼$4.74Volume29,934 shsAverage Volume554,861 shsMarket Capitalization$184.98 millionP/E RatioN/ADividend YieldN/ABeta0.33 ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Veru Inc. operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which is under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil and Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate. The company's oncology drug candidate includes VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-111, an oral alpha and beta tubulin inhibitor, which is under Phase 1b/2 study for the treatment of metastatic prostate, breast, endometrial, ovarian, and pancreatic cancers. It serves agencies, health care distributors, non-government organizations, ministries of health, and other governmental agencies through distributors and retailers primarily in the United States, Brazil, Spain, France, and the United Kingdom. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingVeru has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.50, Veru has a potential upside of 175.7% from its current price of $2.72.Amount of Analyst CoverageVeru has only been the subject of 1 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesVeru has received 232 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVeru has received 170 “underperform” votes. (Add your “underperform” vote.)Community SentimentVeru has received 57.71% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Veru and other stocks. Vote “Outperform” if you believe VERU will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VERU will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVeru does not currently pay a dividend.Dividend GrowthVeru does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Veru insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 26.10% of the stock of Veru is held by insiders.Percentage Held by InstitutionsOnly 16.33% of the stock of Veru is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Veru are expected to grow in the coming year, from ($0.14) to ($0.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veru is -18.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Veru is -18.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVeru has a P/B Ratio of 5.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.41 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Fabricated rubber products, not elsewhere classified Sub-IndustryPersonal Products SectorMedical Current SymbolNASDAQ:VERU Previous Symbol CUSIP31446210 CIK863894 Webwww.veruhealthcare.com Phone305-509-6897Debt Debt-to-Equity Ratio0.07 Current Ratio1.04 Quick Ratio0.68Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$31.80 million Price / Sales5.82 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book5.44Profitability EPS (Most Recent Fiscal Year)($0.19) Net Income$-12,020,000.00 Net Margins-25.53% Return on Equity-31.14% Return on Assets-18.27%Miscellaneous Employees171 Outstanding Shares68,007,000Market Cap$184.98 million Next Earnings Date8/13/2020 (Confirmed) OptionableOptionable $2.72 -0.31 (-10.23 %) (As of 08/13/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive VERU News and Ratings via Email Sign-up to receive the latest news and ratings for VERU and its competitors with MarketBeat's FREE daily newsletter. Veru (NASDAQ:VERU) Frequently Asked Questions How has Veru's stock been impacted by COVID-19 (Coronavirus)? Veru's stock was trading at $3.20 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VERU shares have decreased by 15.0% and is now trading at $2.72. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Veru? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Veru. When is Veru's next earnings date? Veru is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Veru. How were Veru's earnings last quarter? Veru Inc (NASDAQ:VERU) announced its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.01) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.04) by $0.03. The firm had revenue of $9.94 million for the quarter, compared to analyst estimates of $11.06 million. Veru had a negative return on equity of 31.14% and a negative net margin of 25.53%. View Veru's earnings history. What price target have analysts set for VERU? 2 brokerages have issued 12-month target prices for Veru's shares. Their forecasts range from $6.00 to $9.00. On average, they expect Veru's share price to reach $7.50 in the next year. This suggests a possible upside of 175.7% from the stock's current price. View analysts' price targets for Veru. Has Veru been receiving favorable news coverage? Headlines about VERU stock have trended extremely negative this week, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Veru earned a news impact score of -4.1 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news about Veru. Are investors shorting Veru? Veru saw a increase in short interest in June. As of June 15th, there was short interest totaling 304,800 shares, an increase of 41.8% from the May 31st total of 215,000 shares. Based on an average daily trading volume, of 427,600 shares, the short-interest ratio is currently 0.7 days. Currently, 0.6% of the shares of the stock are short sold. View Veru's Short Interest. Who are some of Veru's key competitors? Some companies that are related to Veru include Estee Lauder Companies (EL), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), Medifast (MED), Prestige Consumer Healthcare (PBH), USANA Health Sciences (USNA), Inter Parfums (IPAR), Revlon (REV) and Nature's Sunshine Products (NATR). View all competitors. What other stocks do shareholders of Veru own? Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), OrganiGram (OGI), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Vaxart (VXRT), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Kadmon (KDMN) and Inovio Pharmaceuticals (INO). Who are Veru's key executives? Veru's management team includes the following people: Dr. Mitchell S. Steiner M.D., F.A.C.S, Chairman, Pres & CEO (Age 58)Dr. Harry Fisch, Vice Chairman & Chief Corp. Officer (Age 60)Mr. O. B. Parrish, Co-Founder & Director (Age 86)Ms. Michele Greco, CFO, Exec. VP of Fin. & Chief Admin. Officer (Age 60)Dr. K. Gary Barnette Ph.D., Chief Scientific Officer (Age 51) What is Veru's stock symbol? Veru trades on the NASDAQ under the ticker symbol "VERU." Who are Veru's major shareholders? Veru's stock is owned by a number of institutional and retail investors. Top institutional investors include Wedge Capital Management L L P NC (0.43%), EAM Investors LLC (0.23%), Bank of New York Mellon Corp (0.20%), California Public Employees Retirement System (0.16%), UBS Group AG (0.11%) and New York State Common Retirement Fund (0.07%). Company insiders that own Veru stock include Harry Fisch, Jesus Socorro, K Gary Barnette, Michele Greco and Mitchell Shuster Steiner. View institutional ownership trends for Veru. Which major investors are selling Veru stock? VERU stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., EAM Investors LLC, and Wedge Capital Management L L P NC. View insider buying and selling activity for Veru. Which major investors are buying Veru stock? VERU stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, New York State Common Retirement Fund, American International Group Inc., SG Americas Securities LLC, HighTower Advisors LLC, UBS Group AG, California Public Employees Retirement System, and Leap Investments LP. Company insiders that have bought Veru stock in the last two years include Harry Fisch, Jesus Socorro, K Gary Barnette, and Michele Greco. View insider buying and selling activity for Veru. How do I buy shares of Veru? Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Veru's stock price today? One share of VERU stock can currently be purchased for approximately $2.72. How big of a company is Veru? Veru has a market capitalization of $184.98 million and generates $31.80 million in revenue each year. The company earns $-12,020,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Veru employs 171 workers across the globe. What is Veru's official website? The official website for Veru is www.veruhealthcare.com. How can I contact Veru? Veru's mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The company can be reached via phone at 305-509-6897 or via email at [email protected] This page was last updated on 8/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
